Compare MRBK & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | ALEC |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.3M | 262.7M |
| IPO Year | 2018 | 2019 |
| Metric | MRBK | ALEC |
|---|---|---|
| Price | $20.17 | $2.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $20.00 | $4.83 |
| AVG Volume (30 Days) | 119.3K | ★ 609.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | ★ 30.34 | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | $6,316,000.00 | ★ $21,045,000.00 |
| Revenue This Year | $25.40 | $18.36 |
| Revenue Next Year | $8.15 | N/A |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $11.17 | $0.98 |
| 52 Week High | $21.59 | $3.40 |
| Indicator | MRBK | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 54.35 |
| Support Level | $18.32 | $1.89 |
| Resistance Level | $20.86 | $2.57 |
| Average True Range (ATR) | 0.54 | 0.19 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 51.25 | 55.38 |
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.